ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,412Medicare Part D Prescriptions Filled, Including Refills

Rank: 151 out of 1111

$495K Total Retail Price of All Prescriptions

Rank: 226 out of 1111

229 Patients Receiving at Least One Drug in Part D
58%Patients 65 Years and Older
59% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oklahoma
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

22% of this provider’s 229 patients filled at least one prescription for a schedule three drug, compared to an average of 18%.

Risky Drugs to Seniors

4% of this provider’s 6,354 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

45 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oklahoma
OMEPRAZOLE 409 247 1 4
KLOR-CON 8 393 279 10 2 120
FUROSEMIDE 367 264 3 6
ENALAPRIL MALEATE 364 253 4 56
RANITIDINE HCL 351 221 5 29
SYNTHROID 326 229 6 63
HYDROCODONE-ACETAMINOPHEN 296 101 S3 7 1
SIMVASTATIN 292 231 8 5
AMLODIPINE BESYLATE 283 215 9 7
GABAPENTIN 265 123 10 10
LOSARTAN-HYDROCHLOROTHIAZIDE 242 141 11 72
IBUPROFEN 222 175 12 66
LOSARTAN POTASSIUM 217 155 13 34
MELOXICAM 210 116 14 18
TRAMADOL HCL 205 131 15 13
METFORMIN HCL 200 112 16 8
GLIPIZIDE ER 185 108 17 99
HYDROCHLOROTHIAZIDE 170 138 18 11
METOPROLOL TARTRATE 163 81 19 12
ATENOLOL 143 94 20 22
GEMFIBROZIL 130 87 21 92
TRAZODONE HCL 127 57 22 32
AMITRIPTYLINE HCL 123 42 R 23 64
CRESTOR 122 115 24 33
CARVEDILOL 121 93 25 21
CYCLOBENZAPRINE HCL 118 28 R 26 37
ZOLPIDEM TARTRATE 114 57 27 16
SERTRALINE HCL 104 69 28 24
LEVEMIR FLEXPEN 93 49 29 178
CITALOPRAM HBR 93 50 29 14
OXYBUTYNIN CHLORIDE 88 56 31 110
FLUNISOLIDE 87 24 32 201
ACETAMINOPHEN-CODEINE 84 28 S3 33 140
NOVOFINE 84 59 33 255
MENEST 76 59 R 10 35 274
NOVOLOG FLEXPEN 71 50 36 212
INSULIN SYRINGE 67 58 37 167
CELEBREX 63 38 38 81
TAMSULOSIN HCL 63 52 38 28
SUCRALFATE 61 29 40 125
NAPROXEN 60 38 41 85
VENLAFAXINE HCL ER 59 22 42 105
SPIRONOLACTONE 58 47 43 83
METOCLOPRAMIDE HCL 58 33 43 130
CLOPIDOGREL 58 50 43 30
PREDNISONE 57 26 46 48
PANTOPRAZOLE SODIUM 57 46 46 50
TRILIPIX 55 31 48 197
LISINOPRIL 54 44 49 2
DILTIAZEM ER 53 36 50 158
ALLOPURINOL 51 43 51 36
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 22, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.